Biocytogen

07/31/2024

Check out the latest blog.

Explore how humanized mice are transforming lab findings into real-life therapeutics with Biocytogen’s cutting-edge mouse models.

06/21/2024

🚀 Exciting News! 🚀

Biocytogen has been awarded a U.S. patent for our RenLite® fully human common light chain mouse platform! This breakthrough highlights our dedication to innovation in biotech.

🔬 The RenLite® platform simplifies bispecific antibody production and enhances their properties, thanks to our proprietary SUPCETM technology. We've created a robust library of antibodies targeting over 200 TAA targets, accelerating bispecific antibody and ADC therapies.

🌍 Our RenMice® series, including RenMab™, RenNano®, and RenTCR™, is globally recognized, with partnerships involving top multinational corporations like Merck KGaA and Janssen.

For more information, visit: Biocytogen

06/07/2024

🌞 Welcome Summer with Biocytogen! 🌞

You are cordially invited to celebrate the summer season with us. Join Biocytogen for a Biotech Happy Hour at the Lighthouse Cafe in South San Francisco. Enjoy a complimentary drink, network with industry colleagues, and meet the Biocytogen team in the heart of one of the world’s largest biotech hubs. Register here: https://ow.ly/A2Fu50SbPkg

We look forward to seeing you there!

06/05/2024

🌟 Ready to make an impact? Join our Boston team! 🌟 Calling all driven individuals with a passion for innovation and collaboration. Check out our exciting open roles in biotech now!

Unleash your potential and make a difference with us. Contact [email protected] to learn more! 🚀 Biocytogen Careers: https://lnkd.in/eDb66tP

➡ Scientist/Sr. Scientist for In Vitro Pharmacology: https://lnkd.in/e2V8YaWT

➡ Senior Scientist for In Vivo Pharmacology: https://lnkd.in/epSpgjgE

➡ Pharmacology Research Associate: https://lnkd.in/eyEF3QSq

➡ Business Dev Manager - Product & Services: https://lnkd.in/efNddXiV"

06/04/2024

🧀🐭 Happy National Cheese Day from Biocytogen! 🐭🧀

Our humanized mice are pretty "cheesy" about science! While they don't actually eat cheese, they do help us advance groundbreaking research and therapies. Who knew mice could be so pivotal in unlocking human health mysteries?

Let's celebrate with a virtual slice of cheese for our mighty mice heroes! 🧀🐭

05/15/2024

CD47 is instrumental in cancer progression by aiding immune evasion, promoting angiogenesis, and facilitating tumor cell survival and metastasis. Through its interaction with macrophage receptors, CD47 prevents the phagocytosis of cancer cells, enabling them to evade immune detection. Additionally, CD47 signaling stimulates the formation of new blood vessels, supporting tumor growth and metastasis. Check out our B-hCD47 mice: https://biocytogen.com/products/humanized-immune-checkpoint-mice/b-hcd47-mice/

05/14/2024

🚀Revolutionizing Breast Cancer Treatment: Explore Our Cutting-Edge Antibodies and ADCs!

🎗️With 2.3M new cases and 670K fatalities yearly, breast cancer necessitates innovative solutions. Triple-negative breast Cancer (TNBC) presents formidable challenges, but our novel assets offer hope:

✔️ Bispecific ADCs like BCG023 & BCG033 show promising efficacy in preclinical studies.
✔️ Monoclonal antibodies (mAbs) against Nectin-4, FGFR2b, CEACAM6, and ROR1 exhibit high target affinity and species cross-reactivity.

Catch our poster C017 “Generation of a Fully Human Antibody Library and Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates and Other Antibody-Based Therapeutics” at 2024 on May 16th or reach out for data and partnership opportunities: [email protected].

05/14/2024

Day 2 at ! Swing by booth #23 for a chat and learn about our BioMice and Renbiologics assets, ranging from preclinical animal models and pharmacology evaluation services to antibody assets for licensing. https://biocytogen.com/pegs-boston-2024/

PEGS Boston is taking place from May 13-17 at the Omni Hotel at the Seaport! Our team will be at Booth #23 and will also be presenting a poster titled: "Generation of a Fully Human Antibody Library and Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates and Other Antibody-Base...

05/13/2024

Lung cancer, a primary contributor to cancer-related deaths, impacts millions globally. At Biocytogen, we are pioneering the advancement of novel therapeutic options for non-small cell lung cancer (NSCLC) through the discovery of fully human monoclonal antibodies (mAbs) and bispecific antibody-drug conjugates (bsADCs).

Our anti-PD-L1 mAb demonstrates robust blocking activity and in vivo efficacy, while our anti-TNFR2 mAb exhibits potent ADCC effect and agonist activity. Additionally, our TAA-targeting mAbs and novel bsADCs display high target affinity and superior anti-tumor activity in preclinical models.

Download the poster “Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)” to learn more: https://biocytogen.com/posters/festival-of-biologics-2024-generation-of-a-taa-antibody-library-to-support-the-development-of-antibody-drug-conjugates-adc/

05/10/2024

Sarcomas, the second most common type of solid tumor affecting children and adolescents, encompasses approximately 100 distinct subtypes, originating from diverse tissues such as bone and muscle. Conventional treatment approaches often fall short, particularly in cases diagnosed at advanced stages.

But here's hope! We have pioneered the development of monoclonal antibodies (mAbs) and TCR-mimic antibodies for TCRm-T cell therapy aimed at treating sarcomas. These innovative therapies target either the tumor immune microenvironment or directly attack cancer cells. Download our NY-ESO-1/HLA-A02 poster to learn more: https://biocytogen.com/posters/preclinical-application-of-a-fully-human-tcr-mimic-antibody-developed-to-target-ny-eso-1-hla-a02/

Biocytogen’s TCRm antibody discovery platform combines unique immune technology with a multiplex screening method to obtain a high-affinity NY-ESO-1/HLA-A02 antibody, which can bind and specifically kill HLA-A02-positive cell lines presenting NY-ESO-1. This TCRm platform overcomes the limitation o...